Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Down Syndrome Gene polynucleotide having SEQ ID NO:
- 1 in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide of 18 to 22 nucleotides in length that targets and specifically hybridizes to a region of a natural antisense oligonucleotide of the Down Syndrome Gene polynucleotide (DYKR1) selected from SEQ ID NO;
3 or 4;
thereby upregulating a function of and/or the expression of the Down Syndrome Gene polynucleotide in patient cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Down Syndrome Genes.
195 Citations
11 Claims
-
1. A method of upregulating a function of and/or the expression of a Down Syndrome Gene polynucleotide having SEQ ID NO:
- 1 in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one antisense oligonucleotide of 18 to 22 nucleotides in length that targets and specifically hybridizes to a region of a natural antisense oligonucleotide of the Down Syndrome Gene polynucleotide (DYKR1) selected from SEQ ID NO;
3 or 4;
thereby upregulating a function of and/or the expression of the Down Syndrome Gene polynucleotide in patient cells or tissues in vivo or in vitro. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- 1 in patient cells or tissues in vivo or in vitro comprising;
-
10. A method of upregulating a function of and/or the expression of a Down Syndrome Gene in mammalian cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Down Syndrome Gene polynucleotide having SEQ ID NO;
4, wherein said at least one siRNA oligonucleotide has at least 95% sequence identity to a complementary sequence of at least about 19-30 consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Down Syndrome Gene polynucleotide having SEQ ID NO;
1; and
, upregulating a function of and/or the expression of a Down Syndrome Gene in mammalian cells or tissues in vivo or in vitro.- View Dependent Claims (11)
Specification